FindTrial
Sign In

Eight weeks of low dose hCG priming in women with diminished ovarian reserve undergoing IVF/ICSI – a randomized controlled trial

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2025-521234-28-00
Enrollment
80
Registered
2025-06-03
Start date
2025-09-10
Completion date
Unknown
Last updated
2025-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility, diminished ovarian reserve.

Brief summary

The number of oocytes retrieved after hCG vs placebo priming

Detailed description

Antral follicle count, AMH, number of follicles, number of fertilized eggs, number of cleaved day 2 embryos, number of good and top quality day 2 embryos, number of blastocysts, cycle cancellation rate, Reproductive hormone levels, granulosa cell receptor expression, prenancy and live birth rates

Interventions

DRUGNatriumklorid 9 mg/ml (0
DRUG5 ml injektionsvæske)
DRUGOvitrelle 250 micrograms/0.5 mL solution for injection in pre-filled syringe

Sponsors

Rigshospitalet
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to 64 Years

Design outcomes

Secondary

MeasureTime frame
Antral follicle count, AMH, number of follicles, number of fertilized eggs, number of cleaved day 2 embryos, number of good and top quality day 2 embryos, number of blastocysts, cycle cancellation rate, Reproductive hormone levels, granulosa cell receptor expression, prenancy and live birth rates—

Primary

MeasureTime frame
The number of oocytes retrieved after hCG vs placebo priming—

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026